Tag: Asterias Biotherapeutics

September 12, 2018

Asterias Provides 24 Month Cohort 2 Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury

Asterias Biotherapeutics (NYSE:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular...
July 12, 2018

Asterias Biotherapeutics Announces New Exclusive License Agreement with The Regents of the University of California

Asterias Biotherapeutics (NYSE:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular...
March 16, 2018

Asterias Biotherapeutics Reports Fourth Quarter and Full Year 2017 Financial Results

Asterias Biotherapeutics, Inc. (NYSE American:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination...
March 1, 2018

Asterias Provides Update for its AST-OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury

Asterias Biotherapeutics (NYSE:AST), a biotechnology company dedicated to developing cell-based therapeutics to treat neurological conditions associated with demyelination and cellular...
February 15, 2018

Asterias Expands Global IP Portfolio with New Patents

Asterias Biotherapeutics (NYSE:AST), a biotechnology company dedicated to developing regenerative medicine therapeutics to treat neurological conditions associated with de-myelination and...
August 30, 2017

Asterias Shares Publication on Data for AST-OPC1

Asterias Biotherapeutics announced the publication of a peer-reviewed journal describing the efficacy and safety data from a preclinical study on...
August 23, 2017

Asterias Biotherapeutics Gets Additional Clinical Site for Study

Asterias Biotherapeutics announced the addition of the Washington University School of Medicine in St. Louis as a clinical site in...